2026 Q1 Portfolio Activity
In 2026 Q1, Saturn V Capital Management LP maintained a portfolio of 24 distinct positions. The most significant new addition was CANDEL THERAPEUTICS INC, now representing 2.57% of the total fund value. They heavily accumulated shares in IMMIX BIOPHARMA INC, increasing the position by 23.2%. The fund also reduced its exposure to COGENT BIOSCIENCES INC by 48.5%.
Position History
hover any row below to update
Loading…
Total Positions
24
Quarter
2026 Q1
Top Holding
ALMS (12.8%)
Top 10 Concentration
77.0%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-24 of 24
Saturn V Capital Management LP Full Holdings List — 2026 Q1
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
ALMS
ALUMIS INC
|
Healthcare | 12.77% | 5.62% |
#1
8
Prev: #9
|
6.5 |
—
|
66,122 | 2.1% |
P
S
|
3,202,075 | $70,541,712 |
$10.01
+90.3%
|
2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | ||
|
AMLX
AMYLYX PHARMACE...
|
Healthcare | 10.95% | 9.97% |
#2
Prev: #2
|
6.0 |
—
|
-146,602 | -3.3% |
P
S
|
4,349,885 | $60,463,402 |
$10.06
+29.4%
|
2023 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | ||
|
ABVX
ABIVAX SA
|
Healthcare | 10.94% | 16.07% |
#3
2
Prev: #1
|
5.5 |
—
|
-106,483 | -16.4% |
P
S
|
542,696 | $60,429,200 | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
PCVX
VAXCYTE INC
|
Healthcare | 8.68% | 6.77% |
#4
1
Prev: #5
|
4.5 |
—
|
25,592 | 3.2% |
P
S
|
824,532 | $47,913,555 | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
PHVS
PHARVARIS N V
|
Healthcare | 6.15% | 5.81% |
#5
2
Prev: #7
|
5.0 |
—
|
61,369 | 5.4% |
P
S
|
1,201,402 | $33,939,606 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
IMMX
IMMIX BIOPHARMA...
|
Healthcare | 6.09% | 2.88% |
#6
9
Prev: #15
|
4.9 |
—
|
694,416 | 23.2% |
P
S
|
3,693,585 | $33,648,559 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CELC
CELCUITY INC
|
Healthcare | 5.83% | 5.80% |
#7
1
Prev: #8
|
2.8 |
—
|
-35,191 | -11.1% |
P
S
|
281,904 | $32,176,523 | 2024 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
JAZZ
JAZZ PHARMACEUT...
|
Healthcare | 5.58% | 7.74% |
#8
4
Prev: #4
|
2.2 |
—
|
-85,109 | -34.3% |
P
S
|
162,961 | $30,807,777 | 2025 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
IRON
DISC MEDICINE I...
|
Healthcare | 5.21% | 4.35% |
#9
1
Prev: #10
|
5.1 |
—
|
151,497 | 50.8% |
P
S
|
449,926 | $28,768,268 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
XFOR
X4 PHARMACEUTIC...
|
Healthcare | 4.83% | 4.26% |
#10
1
Prev: #11
|
3.9 |
—
|
656,116 | 11.3% |
P
S
|
6,456,646 | $26,665,948 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
COGT
COGENT BIOSCIEN...
|
Healthcare | 4.37% | 7.93% |
#11
8
Prev: #3
|
1.7 |
—
|
-590,429 | -48.5% |
P
S
|
626,635 | $24,119,181 | 2023 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
MNPR
MONOPAR THERAPE...
|
Healthcare | 3.43% | 3.90% |
#12
Prev: #12
|
3.4 |
—
|
19,925 | 6.1% |
P
S
|
345,626 | $18,936,849 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
DYN
DYNE THERAPEUTI...
|
Healthcare | 3.17% | 6.42% |
#13
7
Prev: #6
|
1.3 |
—
|
-822,007 | -46.0% |
P
S
|
966,609 | $17,524,621 | 2025 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
IVVD
INVIVYD INC
|
Healthcare | 2.58% | 3.51% |
#14
1
Prev: #13
|
3.5 |
—
|
3,213,698 | 41.5% |
P
S
|
10,949,084 | $14,233,809 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CADL
CANDEL THERAPEU...
|
Healthcare | 2.57% | — |
#15
Prev: #—
|
4.5 |
—
|
2,896,588 | — |
NEW
|
2,896,588 | $14,193,281 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
OCS
OCULIS HOLDING ...
|
Healthcare | 2.49% | 1.89% |
#16
Prev: #16
|
2.0 |
—
|
no change | no change |
P
S
|
516,761 | $13,740,675 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
OVID
OVID THERAPEUTI...
|
Healthcare | 1.68% | 0.75% |
#17
2
Prev: #19
|
3.7 |
—
|
1,666,666 | 66.7% |
P
S
|
4,166,666 | $9,249,999 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
IKT
INHIBIKASE THER...
|
Healthcare | 1.18% | 1.45% |
#18
1
Prev: #17
|
1.0 |
—
|
6,646 | 0.2% |
P
S
|
3,863,445 | $6,490,588 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ZURA
ZURA BIO LTD
|
Healthcare | 0.80% | — |
#19
Prev: #—
|
3.8 |
—
|
739,960 | — |
NEW
|
739,960 | $4,402,762 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ANRO
ALTO NEUROSCIEN...
|
Healthcare | 0.36% | — |
#20
Prev: #—
|
3.6 |
—
|
88,999 | — |
NEW
|
88,999 | $2,000,698 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
N/A
SATELLOS BIOSCI...
|
|
Unknown | 0.36% | — |
#21
Prev: #—
|
3.6 |
—
|
350,000 | — |
NEW
|
350,000 | $1,970,500 | — | 13F Filing | 2026-03-31 | 2026-05-15 | ||
|
IVA
INVENTIVA SA
|
Healthcare | 0.00% | 0.24% |
Sold All 😨
(Was: #20) |
0.0 |
—
|
-283,166 | -100.0% |
CLOSED
|
— | $— | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CNTA
CENTESSA PHARMA...
|
Healthcare | 0.00% | 1.30% |
Sold All 😨
(Was: #18) |
0.0 |
—
|
-282,692 | -100.0% |
CLOSED
|
— | $— | 2025 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
OCUL
OCULAR THERAPEU...
|
Healthcare | 0.00% | 3.35% |
Sold All 😨
(Was: #14) |
0.0 |
—
|
-1,504,880 | -100.0% |
CLOSED
|
— | $— | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 |
Showing 1-24 of 24 holdings